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SummaRy
Introduction. In 2014, a group of Polish epilepsy experts published recommendations for antiepileptic 
drug (AED) use in adults with epilepsy. Selection of AEDs was based on the registration and reimburse-
ment status in Poland, evidence of efficacy, and the personal views and experiences of the epilepsy prac-
titioners.
method. In 2018 previous recommendations were reviewed by the ad hoc group consisting of the authors 
of the original paper and additional epilepsy experts. As a result of joint work and reaching a consensus, 
an updated version of these recommendations has been prepared.
Discussion and recommendations. This update focuses on the epileptic seizure type treatment recom-
mendations for initial monotherapy and add-on treatment in adult patients. Some new relevant aspects 
of treatment with AEDs are addressed, including information on the safety of valproic acid (VPA) in wom-
en of childbearing potential.
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INTRODuCTION
In 2014, a group of Polish epilepsy experts published 
recommendations of the Polish Society of Epileptol-
ogy (PSE) for antiepileptic drug (AED) treatment of 
epileptic seizures in adult patients (Jędrzejczak et al., 
2014). The presented therapy outlines and drug selec-
tion were based on the registration of AEDs, their re-
imbursement status in Poland, daily practice and per-
sonal views and experiences of epilepsy practitioners, 
as well as on the guidelines for the treatment of epi-
lepsy published by the International League Against 
Epilepsy (Glauser et al., 2006), American Academy of 
Neurology (French et al., 2004a; 2004b), Scottish In-
tercollegiate Network Guidelines (SIGN, 2003) and the 
British Institute for Clinical Excellence (NICE, 2004). 
 In 2018, these recommendations were reviewed by the 
appointed, extended group of Polish experts from the 
Board of the PSE, the Foundation of Epileptology and 
the National Consultant in Neurology. As a result of 
joint work and reaching a consensus, an updated ver-
sion of these recommendations has been prepared. This 
update primarily concerns information on the safety of 
valproic acid (VPA) in women of childbearing poten-
tial and modified recommendations for the treatment 
of monotherapy in patients with newly diagnosed epi-
lepsy and drug subsequent selection in add-on therapy 
in adult patients. Update of these recommendations was 
aimed to meet the expectations of Polish neurologists 
as well as for decision makers in the national health-
care system. The present recommendations, as were the 
previous ones, are only general indications, not a set of 
mandatory rigid rules to follow.
mETHOD
For the purpose of developing the recommendations, 
the following definitions have been used: monother-
apy refers to the first-line AEDs, used usually as first 
in the therapy. If the chosen drug does not give the ex-
pected beneficial effect (lack of efficacy and/or side ef-
fects), another drug out of first line category can be 
used (an alternative monotherapy).
Depending on the clinical situation, alternative mon-
otherapies with first-line drugs or add-on therapy may 
be introduced.
Add-on therapy – a therapeutic option in which an-
other drug from the first or second and third line drugs 
is added to the first-line drug.
The third-line drug can be used when the current 
therapy with the use of first- and second-line drug is 
ineffective. Before choosing a third-line medication, it’s 
recommended to consult with a center specializing in 
epilepsy to verify diagnosis, consider a different com-
bination of AEDs, or consider other non-pharmacolog-
ical treatments, including neurosurgical treatment. Al-
location of the AED to first, second and third line was 
based on a review of the relevant latest literature on dif-
ferent treatment strategies, level of evidence for AEDs 
efficacy, international guidelines (Kanner et al., 2018a; 
2018b), drug status in Poland (registration, availabili-
ty and reimbursement) and clinical and daily use ex-
perience. Each member of the appointed group of ex-
perts expressed his/her comments, and after reaching 
a consensus, recommendations were made.
DISCuSSION aND RECOmmENDaTIONS
The aim of epilepsy treatment is to enable the patients 
with epilepsy to achieve satisfactory adaptation to the 
demands of life and to lead lifestyles consistent with 
their capabilities. In particular, it is about complete sei-
zure control or substantial decrease of its number with 
the least possible side effects of the treatment. The es-
sential improvement in the standard and quality of life is 
in line with the patient’s perceived decrease in the num-
ber of seizures (Harden et al., 2007). On the other hand, 
however, it is known that people with epilepsy in their 
everyday life are exposed to the vast variety of objec-
tive and subjective burdens resulting from their illness 
(de Boer et al., 2008, Mula and Cock, 2015). Clinicians 
involved in epilepsy treatment should focus equally on 
seizure control, as well as on improving the psycho-
social functioning of patients with epilepsy. The need 
of the sense of independence and self-reliance of peo-
ple with epilepsy in overcoming various psychosocial 
barriers and superstitions is increasingly being raised.
The decision to choose an AED is the responsibility 
of the neurologist. However, the general rules of man-
agement and treatment should be known to the general 
practitioners, as well as to other specialists involved in 
the therapeutic process of epilepsy patients at different 
stages of their lives. This is particularly important as 
the comorbidity of other somatic and mental diseases 
in patients with epilepsy is more frequent than in the 
general population (Tellez-Zenteno et al., 2005; 2007; 
Majkowska-Zwolińska et al., 2008). This results in co-
medication and potential interactions between differ-
ent drugs (Patsalos et al., 2002, Majkowska-Zwolińska 
et al., 2011).
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The choice of an AED primarily depends on the effi-
cacy of the compound for controlling the patient’s sei-
zure type or in a specific epilepsy syndrome. The deci-
sion should be made on an individual bases and analysis 
of the profit-risk ratio of each currently available treat-
ment option. The key element of therapy is the time of 
its start, the choice of a particular first-line drug and 
the best strategy for patients who did not respond sat-
isfactorily to the initial therapy. The other patient-spe-
cific factors, such as sex, age, comorbidities (including 
hepatic and renal impairment), and other medications 
must be taken into account.
 With currently more than 20 AEDs available for 
the treatment of epilepsy in adults, the choice of drug 
seems to be very vast, but at times it also makes selec-
tion of the most suitable drug a complicated task, even 
for specialists in the field of epileptology.
When to start treatment?
The answer to this question seems simple – when epi-
lepsy is diagnosed. The conceptual definition present-
ed in 2005 by the Working Group of the Internatio-
nal League Against Epilepsy (ILAE), defines epilepsy 
as a brain disorder characterized by an enduring predi-
sposition to generate epileptic seizures and the resulting 
neurobiological, psychological and social consequences 
(Fisher et al., 2005). The conceptual definition of epi-
lepsy implies that for its diagnosis it is enough to have 
at least one unprovoked seizure when there is a high 
risk for the next. This real risk is the subject of discus-
sions and debates.
It is known that after a single unprovoked epileptic 
seizure, the risk of a second seizure is 40–52% (Berg 
and Shinnar, 1991). After two unprovoked, non-febrile 
seizures, the risk of another seizure in the 4-year peri-
od is 73%, and with 95% confidence interval – 59–87%. 
Thus, the approximate risk of subsequent seizures after 
the first two was set at 60–90% (Hauser et al., 1998). On 
this basis, a consensus was reached for the diagnosis of 
epilepsy and, consequently, the initiation of antiepilep-
tic treatment after the second epileptic seizure. From 
a practical point of view, the most important thing is 
to understand that the risk of another seizure after the 
first event varies significantly depending on the char-
acteristics of the patient. In people with risk factors for 
seizures, such as:
•	 an underlying condition (stroke, brain injury etc.);
•	 an abnormal neurological examination;
•	 the presence of epileptiform discharges on EEG;
•	 abnormalities on neuroimaging studies suggesting 
epileptogenic nature;
the likelihood of seizure recurrence after the first one 
may be similar and comparable with the risk of further 
seizures after two unprovoked seizures (Hesdorffer et 
al., 2009). In this case, starting AED treatment seems 
to be justified, especially if another seizure could affect 
the patient’s professional functioning. This was an ar-
gument taken into consideration by the ILAE in devel-
oping a new operational (practical) clinical definition 
of epilepsy in line with the way neurologists treating 
epilepsy think. The Working Group of the ILAE has 
extended the definition of epilepsy (Fisher et al., 2014; 
2017a; 2017b). Epilepsy should be considered as a brain 
disease as defined by one of the following conditions:
•	 at least two unprovoked (or reflex) seizures occur-
ring more than 24 hours apart;
•	 one unprovoked (or reflex) seizure, and a probabil-
ity of further seizures similar to the general recur-
rence risk (at least 60%) after two unprovoked sei-
zures, occurring over next 10 years;
•	 diagnosis of an epilepsy syndrome.
The new practical definition may improve the ef-
fects of the treatment by raising clinicians’ awareness of 
thoughtful management after a single unprovoked sei-
zure. However, since AED therapy, especially in adults, 
is usually planned for many years or even for life, the 
decision to start treatment can have far-reaching con-
sequences and must be based on a very thorough anal-
ysis of the advantages and risk of AEDs.
New classification of epileptic seizures In the pre-
vious and the present recommendations for the selec-
tion of the first, second and third-line treatments, the 
seizures terminology was based on Classification of 
Epileptic Seizures from 1981 (Commission on Classi-
fication and Terminology of the ILAE, 1981). Howev-
er, since the following recommendations relate to the 
choice of treatment for specific types of seizures, a new 
classification of seizures published in 2017 was also 
considered and the differences in the nomenclature 
were addressed (Fisher et al., 2017a; 2017b). The major 
changes in the new classification compared to the pre-
vious one is presented below and in Table 1.
•	 Renaming partial seizures for seizures with a fo-
cal onset.
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•	 Types of seizures can be classified into either focal, 
generalized or with an unknown onset.
•	 Awareness is used as a classifier of seizures with fo-
cal onset (with/without impaired awareness).
•	 Terms such as simple and complex partial and sec-
ondary generalized seizures have been removed.
•	 The new category of focal seizures includes: autom-
atisms, autonomic seizures, behavioral arrest, cog-
nitive, emotional, hyperkinetic, sensory and focal to 
bilateral tonic-clonic.
•	 Atonic, clonic, myoclonic, tonic and epileptic spasms 
may be focal or generalized.
•	 Generalized-onset seizures can also be nonmotor 
(absence): typical absence, atypical absence, myo-
clonic absence, or absence with eyelid myoclonia.
General principles of pharmacological treatment 
of epilepsy
•	 The start of treatment must be preceded by a con-
firmed diagnosis of epilepsy.
•	 The diagnosis and choice of the AED is the respon-
sibility of the neurologist.
•	 Treatment is indicated after two epileptic seizures 
and in special cases it is to consider after the first 
unprovoked seizure in patients with a high risk of 
seizure recurrence and when the expected seizures 
may have serious consequences (e.g. in older adults), 
especially with the presence of:
  – a neurological deficit;
  – an epileptic discharges on EEG;
  – a structural lesion in neuroimaging, considered 
to be epileptogenic.
•	 The explanation to the patient of the possible conse-
quences of seizures and various options for the fur-
ther management is crucial. The patient should be 
properly informed and the final decision about start-
ing treatment should be shared.
•	 Pharmacological treatment of epilepsy should be in-
dividually tailored depending on the type of seizure 
and/or seizure syndrome, co-morbidities and use of 
co-medications. Other relevant factors include age 
of the patient (special care groups – children, wom-
en of childbearing age, people over 65 yr.) and so-
cial factors (education, work, driving license, etc.).
•	 In women of childbearing age, the possible teratogen-
ic effect of AEDs and their potential negative effects 
on the fetus is particularly important. In any case, 
the decision of treatment, its effectiveness, the dose 
and type of AEDs should be carefully considered.
•	 It is recommended to start therapy with one drug 
(monotherapy).
•	 The diagnosis of epilepsy should be verified if appro-
priate treatment with first-line drugs does not pro-
vide seizure control.
•	 If seizures are not controlled or if there are side ef-
fects when using the first drug, a second drug should 
be added (another AED from first line drug group) 
and once the drug is titrated to optimal dose, the 
first drug should be slowly withdrawn (alternative 
monotherapy).
•	 Ad-on therapy is recommended when AED mono-
therapy does not result in seizure cessation.
•	 If ad-on therapy is ineffective or poorly tolerated, 
other second-line or third-line therapy should be 
considered. Especially in the latter situation, a con-
sultation at a specialist center should be considered.
•	 There is always a rule of balance between effective-
ness (measured by the reduction in the number of 
seizures) and the tolerance of side effects.
update of international treatment guidelines in 
focal epilepsy in adults
The rationale of recommendation of AEDs use was 
strongly based upon results of recent guidelines in par-
ticular prepared by the Sub-Commission of the Amer-
ican Academy of Neurology (AAN) and the American 
Epilepsy Society (AES) (Kanner et al., 2018a, 2018b). 
Based on the clinical trial methodology, AAN experts 
identified three categories of recommendation strength 
(levels A, B and C) for monotherapy in new-onset epi-
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Table 1. The new International League Against Epilepsy 2017 operational classification of seizure types (basic version) 
(Fisher et al., 2017a)
FOCaL ONSET GENERaLIZED ONSET uNKNOWN ONSET









Focal to bilateral tonic-clonic Unclassified
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lepsy and add-on therapy in refractory epilepsy. The lat-
est data regarding efficiency and safety includes 8 sec-
ond generation AEDs and 6 newer AEDs, so called third 
generation (eslicarbazepine (ESL), esogabine (EZG – 
its manufacture has been discontinued), lacosamide 
(LCM), perampanel (PER), pregabalin (PGB) and ru-
finamide (RFN) in newly diagnosed epilepsy with a fo-
cal onset (Kanner et al., 2018a). Not all of the AEDs 
are approved and available in Poland. The main con-
clusions of the report are: lamotrigine (LTG), leveti-
racetam (LEV) and zonisamide (ZNS) may be consid-
ered in the treatment of newly diagnosed focal epilep-
sy in adults, and LTG and gabapentin (GBP) especial-
ly considered in patients ≥ 60 years. Analyzed studies 
regarding the treatment of newly diagnosed focal ep-
ilepsy were limited to comparisons between AEDs of 
the first and second generation (and vigabatrin – VGB). 
Felbamate (FBM) and VGB are not recommended for 
newly diagnosed epilepsy because of serious side effects, 
especially since there are other drugs that are both safe 
and effective (Kanner et al., 2018a). The second part of 
the summary of update on the efficacy and tolerance of 
new AEDs in the treatment of refractory epilepsy in-
dicates that immediate release PGB and PER are effec-
tive in drug-resistant focal epilepsy in adults (level A) 
as well as VGB (not the first-line drug due to risk of 
retinopathy) (level A); RFN is effective in the treatment 
of Lennox-Gastaut syndrome (LGS) in add-on therapy 
(level A). The following drugs should be considered in 
drug resistant epilepsy in adults: LCM, ESL and topira-
mate (TPM) extended release (level B). Clobazam and 
extended-release oxcarbazepine (OXC) may be consid-
ered in drug resistant epilepsy in adults (level C) (Kan-
ner et al., 2018b). It should be mentioned that the NICE 
guidelines, which include diagnostic and therapeutic 
procedures in epilepsy and seizures in children, ado-
lescents and adults in primary and specialist medical 
care, were also updated in April 2018. The most impor-
tant new statements concern restrictions regarding the 
use of VPA (NICE, 2018).
Detailed PSE recommendations for selecting 
aEDs depending on seizure type
Detailed recommendations for selection of the AEDs 
in focal seizures and generalized seizures in adult pa-
tients with newly diagnosed epilepsy and drug-resist-
ant epilepsy are presented in Table 2. Most of the rec-
ommendations have not changed since the previous 
publication in 2014, as no many new treatment options 
have become available. The results of studies comparing 
PSE recommendations
Table 2. Recommendation for the choice of AEDs in monotherapy and add-on treatment in adults with epilepsy according 
to seizure type
Type of seizure monotherapy/alternative
monotherapy
I – Line Drugs
Add-on therapy
 II – Line Drugs
Add-on therapy
 III – Line Drugs
Focal (Focal onset) CBZ, GBP, LEV, LTG, OXC, VPA * CBZ, GBP, LCM, LEV, LTG, PGB, 
OXC, TPM, VPA *
BRI, ESL, PB, PHT, PER, RFN, TGB, 
VGB, ZNS
Primary generalized tonic-
clonic (Generalized onset 
motor tonic-clonic) 
LEV, LTG, VPA**,
To consider: CBZ, OXC
CLB, LEV, LTG, TPM, VPA **, ZNS
Myoclonic
(Generalized onset motor 
myoclonic) ***
VPA **
To consider: LEV, LTG
LEV, LTG, TPM, VPA ** CLB, CLN, ZNS, piracetam
(In Dravet Syndrome to consider: 
CBD and STR)
Generalized atonic/tonic





(In Lennox-Gastaut Syndrome to 
consider: CBD)




ESM, LTG, TPM, VPA ** CLB, CLN, LEV, ZNS
  * Contraindicated in women of childbearing potential.
 ** PA treatment must not be used in girls and women, unless alternative treatments are not adequate.
 *** CBZ, OXC, GBP, PHT, PGB, VGB, TGB should not be used.
   Seizure type according to new classification in parenthesis (Fisher et al., 2017b).
   Not all compounds are reimbursed – updates are available on the website of the Ministry of Health and National Health Service.
   AEDs in individual columns are shown in alphabetical order: BRI – brivaracetam, CBD – cannabidiol, CLB – clobazam, CLN – clonazepam,  
   CBZ – carbamazepine, ESM – ethosuximide, ESL – eslicarbazepine, GBP – gabapentin, LCM – lacosamide, LTG – lamotrigine, LEV – levetiracetam,  
   OXC – oxcarbazepine, PB – phenobarbital, PER – perampanel, PGB – pregabalin, PHT – phenytoin, RFN – rufinamide, TGB – tiagabine,  
   TPM – topiramate, STR – stiripentol, VGB – vigabatrin, VPA – valproate, ZNS – zonisamide
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older and newer drugs indicate similar efficacy of both 
groups of drugs in newly diagnosed epilepsy. However, 
new-generation drugs have a more favourable pharma-
cokinetic profile (Chen et al., 2018).
The studies published in recent years (Villanueva et 
al., 2013; 2015; Zadeh et al., 2015) and the positive clin-
ical experience of LCM as add-on therapy indicate that 
this drug is effective and safe in such therapy. It seems 
to be much more effective when given as early add-on 
therapy, i.e. in patients who received one or two previ-
ous AEDs. This became the basis to allocate LCM as 
a drug for use in add-on therapy as second-line drug 
and not a third-line, like in previous recommendations. 
The presented position of the PSE expert group does 
not currently change the LCM reimbursement rules, 
but it may have an impact on this situation, especial-
ly since generic formulations have been available since 
November 2018.
As in previous recommendations some AEDs have 
been left among third-line drugs used in add-on ther-
apy. The reason for allocation of those AEDs is either 
lack of/or little experience of Polish neurologists (de-
spite demonstrated efficacy and safety) or high risk of 
side effects that require special supervision and there-
fore are rarely prescribed (Table 2). One of these drugs, 
retigabine (RTG), was withdrawn from the pharmaceu-
tical market in 2017 due to the occurrence of side effects.
Some epileptic syndromes with childhood onset con-
tinue also in adult patients. Considering that their clin-
ical picture may include several types of seizures, these 
syndromes are included in the table, which contains 
recommendations for treatment of particular types of 
seizures. Recent studies indicate the potential efficacy 
of new drugs such as RFN, stiripentol (STR) and can-
nabidiol (CBD) in the treatment of selected epilepsy 
syndromes (Devinsky et al., 2017; Thiele et al., 2018).
The use of VPa and its derivatives in women of 
childbearing age
When using VPA in girls and women of childbearing 
age, especially in high doses or in polytherapy, the po-
tential risk of malformations and neurodevelopmental 
disorders in a child should always be discussed. VPA 
taken during pregnancy can cause developmental de-
fects in 11% of children and developmental disorders 
in 30–40% of children after birth (Meador et al., 2009, 
Weston et al., 2016; Bromley et al., 2010).
In 2014, the European Medicines Agency (EMA) is-
sued information on extended safety warnings about 
medicines containing VPA due to the risk of serious 
developmental disorders and/or congenital malfor-
mations. Subsequently, a group of safety experts from 
the Pharmacovigilance Risk Assessment Committee 
(PRAC) of the EMA carried out an assessment of the 
measures taken so far to minimize the risk of birth 
defects and developmental disorders and expressed its 
position on March 23, 2018 (European Medicines Agen-
cy, 2018). It states that despite previous recommenda-
tions to better educate patients about the risks associ-
ated with these medicines, women still did not receive 
the right information at the right time. Therefore, the 
new measures strengthen earlier restrictions related to 
the use of valproic acid and its derivatives and to in-
form women about the risks. New activities include the 
ban on the use of this group of drugs in the treatment 
of migraine and bipolar disorder during pregnancy, as 
well as in the treatment of epilepsy, if another effective 
form of treatment is available. VPA treatment must not 
be used in girls and women, including girls under ado-
lescence, unless alternative treatments are not adequate 
and if the conditions of the pregnancy prevention pro-
gram are not met. This program includes: assessment 
of patients for the possibility of pregnancy; pregnancy 
tests; advising patients on the risk of VPA treatment; 
explaining the need for effective contraception during 
treatment; regular (at least once a year) treatment con-
sultation by a specialist and filling out the risk confir-
mation form. During pregnancy, VPA is contraindicat-
ed and alternative therapy should be decided upon ap-
propriate specialist consultations.
Pregnancy Prevention Program
•	 VPA should not be prescribed to girls and women 
of  childbearing age unless no other appropriate 
treatment is available.
•	 Education of the family and/or caretakers.
•	 When a girl experiences menstruation, it is advisa-
ble to contact a specialist and provide appropriate 
information on the risks.
•	 We should aim to convert VPA into alternative treat-
ment in girls before sexual maturity.
Pregnancy test
•	 Before beginning treatment with VPA, pregnancy 
should be excluded.
•	 VPA treatment must not be initiated in women of 
childbearing potential without a negative pregnan-
cy test result (plasma pregnancy test).
Joanna Jędrzejczak et al.
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Contraception
•	 Women of childbearing age who have been pre-
scribed VPA must use effective contraception 
throughout the VPA treatment (e.g. intrauterine 
device) or two complementary methods (including 
barrier methods).
Annual treatment checks performed by a specialist
•	 Once a year, the specialist should assess wheth-
er VPA is the most appropriate treatment (form of 
annual confirmation that the patient has become 
aware of the risk).
Planning pregnancy
•	 If a woman plans to become pregnant, a specialist 
experienced in the treatment of epilepsy needs to re-
assess the treatment of VPA and consider alternative 
treatments before becoming pregnant.
In pregnancy
•	 VPA in the treatment of epilepsy is contraindicated 
in pregnancy unless there is no alternative treatment;
•	 The woman should be referred to a specialist to re-
evaluate the need for VPA treatment and consider an-
other treatment. If the patient needs to receive VPA 
during pregnancy, the lowest effective dose should 
be used. Prenatal monitoring should be implement-
ed in all patients receiving VPA during pregnancy.
The full text of the new restrictions on the use of VPA 
in women of childbearing age and the introduction of 
a contraceptive program is available on the website of 
the Office for Registration of Medicinal Products, Med-
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